https://www.live-feeds.com/feed/novartis-strikes-up-to-7-8-billion-mrna-deal-with-china-s-abogenContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/novartis-strikes-up-to-7-8-billion-mrna-deal-with-china-s-abogenhttps://www.live-feeds.com/feed/novartis-strikes-up-to-7-8-billion-mrna-deal-with-china-s-abogen#u104368Mon, 05 Oct 2026 23:37:06 +0000Novartis has entered a licensing agreement with Chinese startup Abogen Biosciences valued at up to $7.8 billion. The deal centers on an mRNA-encoded in vivo autoimmune T-cell engager. Under the terms, Novartis will license the drug candidate and secure options for additional future therapies from the company. This agreement reflects a broader trend of major pharmaceutical firms increasing their investment and partnership activity within the Chinese biotech market.Why it mattersThe partnership focuses on mRNA technology applied to autoimmune treatments. This move aligns with a wider strategic p